22 unknown, 18 completed, 11 recruiting, 7 not yet recruiting. 42 Phase 2, 18 Phase 1, 6 Phase 3, 5 Not applicable, 1 Early Phase 1.
Follow Advanced Colorectal Cancer: new trials by email Literature Review of Advanced Colorectal Cancer trials Research Report on Advanced Colorectal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer SHR-A1811, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab - Advanced Colorectal Cancer | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 300 | 2026-08-28 | 2026-09-10 |
| A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer MRG007, 5-Fluorouracil / Leucovorin Calcium, Bevacizumab - Advanced Colorectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | Lepu Biopharma Co., Ltd. | 316 | 2026-08-01 | 2026-08-04 |
| Sintilimab Plus Gossypol Acetate in Advanced Colorectal Cancer Sintilimab, Gossypol Acetate - Advanced Colorectal Cancer | Phase 2 | Not yet recruiting | Peking University People's Hospital | 32 | 2026-07-15 | 2026-06-25 |
| Optimal Surveillance Strategy After Positive FIT and Negative Colonoscopy Colonoscopy Surveillance - Advanced Colorectal Cancer, Colo-rectal Cancer | Enrolling by invitation | National Taiwan University Hospital | 1274 | 2026-03-10 | 2026-03-13 | |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer CBI-1214 - Colorectal Cancer, Colorectal Cancer (CRC) | Phase 1 | Recruiting | Cartography Biosciences | 80 | 2026-01-15 | 2026-08-26 |
| Assessment of the Dose Safety and Efficacy of Serine Combined With Fluorouracil Drugs Serine（Oral）, Fluoropyrimidine Drugs - Advanced Colorectal Cancer | Phase 1 | Not yet recruiting | The First Affiliated Hospital of Xinxiang Medical College | 20 | 2025-11-01 | 2025-09-17 |
| Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial Ongericimab + Toripalimab + Bevacizumab + FOLFOX, Ongericimab + Toripalimab + Bevacizumab + FOLFIRI - Advanced Colorectal Cancer | Phase 2 | Recruiting | Shanghai Pudong Hospital | 32 | 2025-08-31 | 2026-07-07 |
| Trial of ProAgio in Advanced/Metastatic Colorectal Cancer ProAgio, FOLFIRI, Bevacizumab - Advanced Colorectal Cancer, Metastatic Colorectal Cancer | Phase 1 | Suspended | University of Alabama at Birmingham | 27 | 2025-07-17 | 2026-10-02 |
| A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer Cetuximabβ combined with Envolimab and mFOLFOX6 - Advanced Colorectal Cancer | Phase 2 | Not yet recruiting | Tao Zhang | 42 | 2025-05-20 | 2025-06-02 |
| Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU mFOLFOX/FOLFIRI ( Standard Chemotherapy) - Advanced Colorectal Cancer | Phase 2 | Recruiting | Chinese PLA General Hospital | 583 | 2025-05-15 | 2026-02-06 |
| TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer TL938 Capsules, Trastuzumab - Colorectal Cancer Metastatic, Advanced Colorectal Cancer | Phase 2 | Recruiting | Suzhou Teligene Ltd. | 80 | 2025-05-13 | 2026-04-28 |
| A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer JS207, JS015, Capecitabine - Advanced Colorectal Cancer | Phase 2 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 60 | 2025-04-23 | 2025-06-24 |
| SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT), Cadonilimab - Advanced Gastric Cancer, Advanced Colorectal Cancer | Phase 1 / Phase 2 | Active not recruiting | Zhang Tao | 26 | 2025-03-20 | 2025-04-27 |
| Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer Defactinib, Cetuximab, Avutometinib - Advanced Colorectal Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 33 | 2025-02-24 | 2026-09-25 |
| A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer B1962 - Advanced Colorectal Cancer | Phase 2 | Not yet recruiting | Tasly Biopharmaceuticals Co., Ltd. | 80 | 2025-02-24 | 2025-02-20 |
| The Role of 18F-FDG and 68Ga-FAPI PET/CT in the Diagnosis and the Efficacy Evaluation of Advanced Colorectal Cancer (peritoneal Metastasis With/without Other Metastases) Advanced Colorectal Cancer | Recruiting | Ruijin Hospital | 30 | 2025-02-01 | 2025-01-22 | |
| Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer RBS2418, Placebo - Metastatic Colorectal Cancer, Advanced Colorectal Cancer | Phase 2 | Recruiting | Riboscience, LLC. | 150 | 2025-01-17 | 2026-05-18 |
| A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification BGB-53038, Tislelizumab, Cetuximab - Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer | Phase 1 | Terminated | BeOne Medicines | 47 | 2024-12-13 | 2026-07-08 |
| SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer SHR-A1811 & Apartinib - Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Yunpeng Liu | 28 | 2024-12-01 | 2024-10-30 |
| Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan SHR-A1811, TAS-102, Regorafenib , Fruquintinib - Advanced Colorectal Cancer | Phase 3 | Active not recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 130 | 2024-03-01 | 2025-07-17 |
Showing 20 of 71. Sign in to see all of them.
Colorectal Neoplasms (18) · Colonic Neoplasms (6) · Neoplasms (5) · Rectal Neoplasms (3) · Neoplasm Metastasis (2) · Appendiceal Neoplasms (1) · Disease (1) · Ovarian Neoplasms (1) · Stomach Neoplasms (1)
Digestive System Diseases (21) · Digestive System Neoplasms (21) · Gastrointestinal Diseases (21) · Gastrointestinal Neoplasms (21) · Intestinal Diseases (21) · Intestinal Neoplasms (21) · Neoplasms by Site (21) · Colonic Diseases (20) · Rectal Diseases (19) · Neoplasms (18) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Colorectal Neoplasms (2) · Neoplastic Processes (2) · Adnexal Diseases (1)
Bevacizumab (9) · Oxaliplatin (8) · Cetuximab (7) · Fluorouracil (7) · Irinotecan (4) · Leucovorin (4) · Capecitabine (3) · regorafenib (3) · trifluridine tipiracil drug combination (3) · Drug Therapy (2) · Folfox protocol (2) · surufatinib (2) · 5'-oleoyl cytarabine (1) · Cryotherapy (1) · Curcumin (1)
Jiangsu Cancer Institute & Hospital (3) · Cancer Trials Ireland (2) · Fujian Cancer Hospital (2) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (2) · Zhejiang Cancer Hospital (2) · AbbVie (prior sponsor, Abbott) (1) · Allist Pharmaceuticals, Inc. (1) · Asan Medical Center (1) · BeOne Medicines (1) · Binex (1) · British Columbia Cancer Agency (1) · Cartography Biosciences (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Chinese Academy of Medical Sciences (1) · Chinese PLA General Hospital (1)
China (35) · United States (15) · South Korea (7) · Belgium (6) · Canada (6) · Spain (6) · Australia (5) · Italy (5) · Germany (4) · Greece (4) · Poland (4) · United Kingdom (4) · France (3) · Ireland (3) · Portugal (3)
Liangjun Zhu (2) · Wangxia Lv (2) · Aimin Zang (1) · Aiping Zhou (1) · Alfredo Budillon, M.D. (1) · Antonio Avallone, M.D. (1) · Bo Liu (1) · C. J. A. Punt, Prof.Dr. (1) · Christine Parseghian, MD (1) · Claire Asher, MD, MPH (1) · Daniela Aust, MD (1) · Francesco Perrone, M.D. (1)
PMID 16873425, PMID 17630036, PMID 21706149, PMID 23692811, PMID 28094194, PMID 32820453, PMID 38166647, PMID 39116902, PMID 39286935, PMID 39658608, PMID 39752885, PMID 41344351, PMID 41487064, PMID 42384131, PMID 42421558
2015 (1), 2016 (1), 2017 (1)